Protocol Number TDE -PH-304 Amendment 5  Confidential  
United Therapeutics Corporation  
Final  Version Dated 20 March 2013  1  
 
 
Protocol TDE -PH-304 
 
 
An Open -Label Extension Trial of UT-15C SR  in Subject s with 
Pulmonary Arterial Hypertension  
 
 
IND# 71,537  
 
EudraCT# 2006 -000804 -18 
 
 
CONFIDENTIAL  
 
 
UNITED THERAPEUTICS CORPORATION  
 
 
55 T.W. Alexander Dr.     United Therapeutics Eur ope Limited  
P. O. Box 14186       
Research Triangle Park, NC 27709    
United Sates of America     United Kingdom  
Phone:     Phone:  
Fax:     Fax:  
 
 
Protocol Date:    18 January  2006  
Amendment 1 Date:   14 February 2007  
Amendment 2 Date:   13 December 2007  
Amendment 3 Date:   28 April 2008  
Amendment 4 Date:   2 March  2009  
Amendment 5 Date:  20 March  2013  
 
 
Confidentiality Statement:  
 
This document i s a confidential, proprietary communication of United Therapeutics 
Corporation and may not be disclosed to parties not associated with the clinical 
investigation or used for any purpose without the prior written consent of © 2013 United 
Therapeutics Corpor ation.  

Protocol Number TDE -PH-304 Amendment 5  Confidential  
United Therapeutics Corporation  
Final  Version Dated 20 March 2013  2 LIST OF CONTACTS FOR STUDY  
Study Sponsor:  
United Therapeutics Corp.  
55 T.W. Alexander Drive  
Research Triangle Park, NC  
27709  
USA  
 
 
 
  
 
 
 
 
 
United Therapeutics Europe 
 
 
 
 
United Kingdom   
 
 
 
 
  
Contract Research 
Organization:  
 
 
 
  
 
 
 
 
 
  
Medical Monitor   
 
 
 
 
 
  
  
SAE Reporting   
 
 
   
 
    
 
  
 
Clinical Laboratory  
Covance Central Laboratories   
 
 
 
 
          
 
 
 
 
  
 
 
 
  
 
 
 
 
 
 
 
 

Protocol Number TDE -PH-304 Amendment 5  Confidential  
United Therapeutics Corporation  
Final  Version Dated 20 March 2013  3 INVESTIGATOR AGREEMENT  
 
I have read the attached protocol entitled “An Open -Label Extension Trial of UT-15C SR  in Subject s with 
Pulmonary Arterial Hypertension” , Amend ment 5 dated 20 March  2013  and agree to abide by all 
provisions set forth therein.  This protocol has been received for information only and must not be 
implemented before all necessary regulatory agency and ethics approval documents have been obtained.  
 
I agree to comply with the International Conference on Harmonisation (ICH) Guideline for Good Clinical 
Practice and applicable Food and Drug Administration regulations/guidelines set forth in 21 Code of 
Federal Regulations Parts 50, 54, 56 and 312 and any lo cal regulations per country . 
 
I agree to ensure that the confidential information contained in this document will not be used for any 
purpose other than the conduct of the clinical investigation without the prior written consent of United 
Therapeutics Corp oration.  
 
I also have read the current Clinical Investigators’ Brochure for UT -15C (treprostinil diethanolamine) and 
acknowledge that review of the information contained in the Clinical Investigators’ Brochure is a 
requirement for investigators before usi ng UT -15C in a clinical trial.   
 
________________________________                       _______________________________  
Signature of Principal Investigator                                 Date  
 
 
_______________________ _________                                              
Printed Name of Principal Investigator                         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protocol Number TDE -PH-304 Amendment 5  Confidential  
United Therapeutics Corporation  
Final  Version Dated 20 March 2013  4 PROTOCOL SUMMARY  
 
Protocol Number:   TDE-PH-304 
 
Protocol Title:  An Open -Label Extension Trial of UT-15C SR  in Subject s with 
Pulmonary Arterial Hypertension  
 
Study Phase:    3 
 
Name of Drug:    UT-15C SR  (treprostinil diethanolamine)  
 
Indication:    Pulmonary Arterial Hypertension  (PAH)  
 
Study Objective s: To provide, or continue to provide, UT-15C SR  for eligible subject s who 
particip ated in protocols TDE-PH-202, TDE-PH-203, TDE -PH-205, TDE-
PH-301, TDE-PH-302, TDE-PH-308, or any additional UT -15C SR 
clinical protocols evaluating  subjects with PAH .  
 
To assess the long -term safety of UT-15C SR  in these subject s through 
assessment of adverse events and laboratory para meters .  
 
To assess the effect of continued therapy with UT-15C SR  on exercise 
capacity after one year of treatment.  
 
Study Design:  This is a multi -center, open -label study for eligible patients who 
participated in  Protocol TDE-PH-202, TDE-PH-203, TDE -PH-205, TDE-
PH-301, TDE-PH-302, TDE-PH-308, or any additional UT -15C SR 
clinical protocols evaluating  subjects with PAH . 
 
Sample Size:  Approximately  900 subject s from protocols TDE-PH-202, TDE-PH-203, 
TDE-PH-205, TDE-PH-301, TDE-PH-302, and TDE -PH-308 plus 
additional subjects from any additional UT -15C SR clinical protocols 
evaluating  subjects with PAH . 
 
Summary of Subject  
Eligibility Criteria:  Participation in stud y TDE-PH-202, TDE-PH-203, TDE -PH-205, TDE-PH-
301, TDE-PH-302, TDE-PH-308 or any additional UT -15C SR clinical 
protocol  is required.  Subjects must complete all assessments in one of 
these studies to be eligible.  
 
Drug Dosage and  
Formulation:  UT-15C Sustained Release Tablets will be provided as 0.25, 0.5, 1, and 
2.5 mg  tablet strengths.  UT -15C SR tab lets may also be provided as  a 
0.125 mg strength, if available .     
  
 For subjects on placebo at the end of the TDE -PH-301, TDE-PH-302, 
and TDE -PH-308 protocols, treatment will be initiated at 0.25 mg twice 
daily (every 12 hours +/ - 1 hour) with dose esca lation of an additional 
0.25 to 0.5 mg twice daily  every 3 days if clinically indicated based upon 
adverse events and signs and symptoms of PAH.   The 0. 125 mg 
strength, if available, may be used throughout the study if a 0.25 mg 
dose increase is not tolera ted and an intermediate dose is required.  
Doses should be optimized  throughout the study .  For subjects on active 
therapy in  TDE-PH-202, TDE -PH-203, TDE -PH-205 TDE-PH-301, TDE-
PH-302, and TDE -PH-308 the initial dose of the open -label  study will be 
Protocol Number TDE -PH-304 Amendment 5  Confidential  
United Therapeutics Corporation  
Final  Version Dated 20 March 2013  5 based u pon their ending dose in the previous  study, and dose 
modification will be based on adverse events and signs and symptoms of 
PAH.  Twice daily(BID) dosing should occur (every 12 hours +/ - 1 hour)  
with dose escalation of an additional 0.25 to 0.5 mg twice d aily every 3 
days if clinically indicated based upon adverse events and signs and 
symptoms of PAH.  Three times (TID) daily dosing for subjects enrolled 
from the TDE -PH-205 study or those subjects transitioning from BID to 
TID dosing, study drug  should be t aken every 6 -8 hours  with dose 
escalation of an additional 0. 125 to 0.25 mg twice daily every 3 days if 
clinically indicated based upon adverse events and signs and symptoms 
of PAH.  All study drug should be administered immediately following 
(~10 minutes)  breakfast and dinner  for BID dosing and with food for TID 
dosing.  
 
Route of Administration:   Oral 
 
Study Visit Schedule:  Study visits will be timed to occur 3, 6, 12, 24,  36 months after each 
subject’s  first exposure to UT-15C SR .  The study will continue  with 
yearly visits beyond 36 months  until either UT-15C SR is approved by 
the appropriate regulatory authorities  or the study is discontinued by the 
sponsor.  Subjects receiving placebo in the previous study  (TDE -PH-301, 
TDE-PH-302, or TDE -PH-308) and sub jects enrolled from the TDE -PH-
202 study who were in Dose Groups 1 or 2 and permanently 
discontinued treatment must be contacted weekly by telephone during 
the first 12 weeks of the open -label study.  Subjects transitioning from 
BID to TID dosing should be  contacted weekly for the first four weeks 
after transitioning.  Monthly telephone calls must be conducted for all 
subjects actively participating in TDE -PH-304, regardless of study drug 
allocation (UT -15C SR or placebo) in the previous study.  In addition to 
the scheduled study visits, all subjects must be seen in the clinic no less 
than once every six months for routine standard of care medical 
evaluation.    
 
Efficacy Assessment:  A 6-Minute Walk  Test with Borg Dyspnea Score will be conducted at the 
study visit occurring  1 year after the subject  first received UT-15C SR . 
 
Safety Assessments:  Adverse events and clinical laboratory parameters  will be assessed 
throughout the study.   
 
Statistical Considerations:  All data will be summarized in tables and listing s. 
 
Sponsor:  United Therapeutics Corporation  
55 T.W. Alexander Dr.  
 P.O. Box 14186  
 Research Triangle Park, NC 27709  
United States of America  
 
 
 
 
 
 
Protocol Number TDE -PH-304 Amendment 5  Confidential  
United Therapeutics Corporation  
Final  Version Dated 20 March 2013  6 TABLE OF CONTENTS  
 
LIST OF CONTACTS FOR STUDY  ................................ ................................ ..........................  2 
INVESTIGATOR AGREEMENT  ................................ ................................ ................................  3 
PROTOCOL SUMMARY ................................ ................................ ................................ .............  4 
TABLE OF CONTENTS  ................................ ................................ ................................ ..............  6 
LIST OF ABBREVIATIONS  ................................ ................................ ................................ ........  8 
1 BACKGROUND AND RATIONALE ................................ ................................ ...................  9 
1.1 Pulmonar y Arterial Hypertension:  Definition of Clinical Problem  ............................  9 
1.2 Treprostinil Background  ................................ ................................ ................................ .. 9 
1.2.1  UT-15C SR Nonclinical  ................................ ................................ ...........................  9 
1.2.2  UT-15C SR Clinical Pharmacology  ................................ ................................ ..... 11 
1.2.3  Remodulin Experience  ................................ ................................ ..........................  13 
1.3 Rationale for Development of Study Drug in Disease/Condition  ............................  13 
1.4 Clinical Hypothesis  ................................ ................................ ................................ .........  14 
2 STUDY OBJECTIVES AND ENDPOINTS  ................................ ................................ ..... 14 
2.1   Study Objectives ................................ ................................ ................................ .............  14 
2.2 Study Endpoints  ................................ ................................ ................................ .............  14 
3 EXPERIMENTAL  PLAN  ................................ ................................ ................................ .... 14 
3.1   Study Design  ................................ ................................ ................................ ...................  14 
3.2 Overall Schedule of Times and Events  ................................ ................................ ...... 15 
3.3 Clinical Assessments  ................................ ................................ ................................ ..... 16 
3.3.1  Efficacy ................................ ................................ ................................ .....................  16 
3.3.2  Safety  ................................ ................................ ................................ .......................  16 
3.4 Number of Centers  ................................ ................................ ................................ .........  17 
3.5 Number of Subjects  ................................ ................................ ................................ ....... 17 
3.6 Estimated Study Duration  ................................ ................................ .............................  17 
4 SUBJECT ELIGIBILITY  ................................ ................................ ................................ ..... 18 
4.1 Subject Inclusion Criteria  ................................ ................................ ..............................  18 
5 SUBJECT ENROLLMENT  ................................ ................................ ................................  19 
5.1 Treatment Assignment  ................................ ................................ ................................ .. 19 
5.2 Randomization  ................................ ................................ ................................ ................  19 
5.3 Blinding  ................................ ................................ ................................ ............................  19 
6 DRUGS AND DOSING  ................................ ................................ ................................ ...... 19 
6.1 Drug Dosage, Administration and Schedule  ................................ ..............................  19 
6.1.1 Twic e Daily Dosing Regimen  ................................ ................................ .................  19 
6.1.2 Transition from Twice to Three Times daily Dosing  ................................ ...........  20 
6.1.3 Three Times (TID) Daily Dosing Regime n ................................ ...........................  20 
6.1.4 Dosing of Study Medication in Relation to Meals  ................................ ................  21 
6.2 Compliance  ................................ ................................ ................................ .....................  21 
7 EXPERIMENTAL PROCEDURES  ................................ ................................ ..................  21 
7.1 Open -Label Phase  ................................ ................................ ................................ .........  21 
8 STUDY TERMINATION  ................................ ................................ ................................ .... 23 
8.1 Subject Discontinuation  ................................ ................................ ................................ . 23 
8.2 Study Discontinuation  ................................ ................................ ................................ .... 23 
8.3 Site Discontinuation  ................................ ................................ ................................ ....... 23 
Protocol Number TDE -PH-304 Amendment 5  Confidential  
United Therapeutics Corporation  
Final  Version Dated 20 March 2013  7 9 ADVERSE EVENT REPORTING  ................................ ................................ ....................  24 
9.1 Definitions  ................................ ................................ ................................ .........................  24 
9.1.1 Adverse Event  ................................ ................................ ................................ ..........  24 
9.1.2 Serious Adverse Event  ................................ ................................ ............................  24 
9.1.3 Expected Adverse Event  ................................ ................................ .........................  24 
9.2 Do cumentation of Adverse Events  ................................ ................................ ...............  25 
9.3 Reporting Responsibilities of the Investigator  ................................ .............................  25 
9.4 Safety Reports  ................................ ................................ ................................ .................  25 
9.5 Pregnancy  ................................ ................................ ................................ .........................  25 
10 DATA MANGEMENT AND STATISTICS  ................................ ................................ ... 26 
11 PACKAGING AND FORMULATION  ................................ ................................ ...............  26 
11.1  Study Drug Content  ................................ ................................ ................................ ....... 26 
11.2  Study Drug Labeling  ................................ ................................ ................................ ...... 26 
11.3  Study Drug Storage and Handling  ................................ ................................ ...............  26 
11.4  Study Drug Supply and Return  ................................ ................................ ....................  26 
11.5  Study Drug Accountability  ................................ ................................ .............................  27 
12 REGULATORY AND ETHICAL OBLIGATION  ................................ ..............................  27 
12.1  Regulatory Requirements  ................................ ................................ .............................  27 
12.2  Informed Co nsent Requirements  ................................ ................................ .................  27 
12.3  Institutional Review Board/Independent Ethics Committee Approval  ....................  27 
12.4  Prestudy Documentation Requi rements  ................................ ................................ ..... 27 
12.5  Subject Confidentiality  ................................ ................................ ................................ ... 28 
12.6  Reporting of Clinical Trial Results  ................................ ................................ ...............  28 
13 ADMINISTRATIVE AND LEGAL OBLIGATIONS  ................................ .........................  28 
13.1  Protocol Amendments and Study Termination  ................................ ..........................  28 
13.2  Study D ocumentation and Storage  ................................ ................................ .............  28 
13.3  Study Monitoring and Data Collection  ................................ ................................ ........  29 
14 REFERENCES  ................................ ................................ ................................ ...................  30 
15 APPENDICES  ................................ ................................ ................................ .....................  31 
APPENDIX A:  Procedure for 6 -Minute Walk Exercise Test and Borg Dyspnea Score
 31 
APPEN DIX B:  Clinical Laboratory Parameters  ................................ ................................  33 
APPENDIX C:  Guidelines and Definitions for Recording Adverse Events  ..................  34 
APPENDIX D:   Expected Adverse Events Listing for UT -15C SR Clinical Studies  .. 36 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protocol Number TDE -PH-304 Amendment 5  Confidential  
United Therapeutics Corporation  
Final  Version Dated 20 March 2013  8 LIST OF ABBREVIATIONS  
 
Abbreviation  Definition  
AE Adverse Event  
ALT Alanine Aminotransferase  
AST Aspartate Aminotransferase  
BID Twice Daily  
ºC Degrees Celsius  
CRF Case Report Form  
EC Ethics Committee  
ERA Endothelin Receptor Antagonist  
FDA Food and Drug Administration  
ºF Degrees Fahrenheit  
GCP  Good Clinical Practice  
GI Gastrointestinal  
ICH International Conference on Harmoni sation  
iMTD Individual Maximum Tolerated Dose  
IRB Independent/ Institutional Review Board  
LDH Lactate  Dehy drogenase  
MedDRA  Medical Dictionary for Regulatory Activities  
mg Milligram  
mL Milliliter  
PAH Pulmonary Arterial Hypertension  
PDE 5 Phosphodiesterase 5  
PGI2 Prostacyclin  
SAE Serious Adverse Event  
SR Sustained Release  
TID Three Times Daily  
UT-15C SR  Treprostinil Diethanolamine  
 
 
 
 
 
 
 
Protocol Number TDE -PH-304 Amendment 5  Confidential  
United Therapeutics Corporation  
Final  Version Dated 20 March 2013  9 1 BACKGROUND AND RATIONALE  
1.1 Pulmonary Arterial Hypertension:  Definition of Clinical Problem  
Pulmonary arterial hypert ension (PAH), which is defined as an elevation in pulmonary arterial pressure 
and pulmonary vascular resistance, is a severe hemodynamic abnormality associated with a variety of 
diseases and syndromes.  Elevation in pulmonary arterial pressure causes an in crease in right ventricular 
afterload, impairing right ventricular function and ultimately leading to inactivity and death.   
 
There are three major factors thought to contribute to the increased pulmonary vascular resistance seen 
in this disease: vasocons triction, remodeling of the blood vessel wall, and thrombosis. There are a 
number of metabolic pathways implicated as contributing to these changes including vasoactive 
mediators such as the vasodilators nitric oxide and prostacyclin, the vasoconstrictor e ndothelin -1, and the 
phosphodiesterase type -5 mediated vasodilation.  These substances affect not only vascular tone but 
also effect vascular remodeling and represent current pharmacologic targets.1  
 
Approved pharmacotherapies  for PAH include: (1)   intravenous prostacyclin (epoprostenol sodium or 
Flolan®)2,3, (2) the prostacyclin analogues, subcutaneous  (SC),   intravenous  (IV), and inhaled treprostinil 
sodium (Remodulin®; Tyvaso®)    and inhaled iloprost (Ventavis®), (3) the oral phosphodiesterase -5 
inhibi tors (PDE5 -I), tadalafil (Adcirca®) and sildenafil (Revatio®); and (4) the oral   endothelin receptor 
antagonist s (ERA)9, 10 , bosentan (Tracleer®) and ambrisentan (Letairis®, Volibris ®).11,12    
1.2 Treprostinil Background  
1.2.1  UT-15C SR  Nonclinical  
UT-15C is a novel salt form of Remodulin® (treprostinil) Injection and Tyvaso® (treprostinil) Inhalation 
Solution, which are approved in the United States and other countries for the treatment of patients with 
PAH. The active pharmaceutical ingredient, treprost inil, exists as the sodium salt in the drug product of 
Remodulin and Tyvaso. Given that the only change to the drug substance synthesis route for UT -15C is 
the diethanolamine addition step, and treprostinil is not altered, the bioactive form of treprostini l 
diethanolamine and treprostinil sodium is predicted to be identical.  Therefore, in addition to the 
nonclinical studies conducted with UT -15C, an extensive amount of pharmacology, pharmacokinetic, and 
toxicology information on treprostinil sodium is avai lable from Remodulin and Tyvaso development.  
During the development of Remodulin, treprostinil sodium was administered SC and / or IV in acute 
toxicity studies, repeat -dose toxicity studies, reproductive toxicity studies, and genotoxicity studies, and 
has a well defined clinical safety profile.  Treprostinil sodium was administered via continuous infusion to 
both rats and dogs in toxicity studies for up to 6 -months, which supported the chronic administration of 
Remodulin to patients.  
In addition to the exte nsive toxicology data with treprostinil sodium, the toxicity and toxicokinetic profiles 
of UT -15C have been evaluated in acute and repeat dose oral toxicity studies of up to 13 weeks in 
duration in rodents and up to 9 months duration in dogs.  UT -15C has a lso been evaluated in 
reproductive -developmental toxicity studies in pregnant rats and rabbits and in an in vivo  rat micronucleus 
assay.  
 
Nonclinical findings from 13 week toxicology studies with UT -15C have included dose dependent, yet 
transient decrease s in mean body weight gain and food consumption in both rats and dogs and soft / 
mucoid stools, diarrhea, and vomitus in dogs.  Many of these findings have been seen previously during 
development of Remodulin and are consistent with prostacyclin induced ef fects.  In addition, post -mortem 
findings in rats administered UT -15C included changes in organ weight data and histological findings 
related to the adrenal gland, heart, spleen, thymus and bone marrow; some of which were not seen with 
Remodulin.  The majo rity of these findings were reversible following a 4 -week recovery period.  Data from 
a 9-month dog study provides additional toxicology information following chronic dosing.  UT -15C was 
reasonably well -tolerated following daily oral administration at dose  levels up to 35  mg/dog/day for 9 
months.  The primary adverse effect was judged to be gastrointestinal disturbance, evidenced by 
increased incidence of soft stools, mucoid stools and diarrhea.  By the end of the study, all dogs were in 
Protocol Number TDE -PH-304 Amendment 5  Confidential  
United Therapeutics Corporation  
Final  Version Dated 20 March 2013  10 good condition.  No  systemic adverse effects were detected as judged by ophthalmology, ECG, clinical 
pathology and histopathological examination.  
 
In vitro  genotoxicity studies with UT -15C have not been conducted; however, data are available for such 
studies using high doses  of Remodulin (treprostinil sodium).  Remodulin (treprostinil sodium) was non -
mutagenic in bacterial reverse mutation assays (Ames assay) at concentrations up to 5,000 mcg/plate 
with and without S9 metabolic activation, and in the mouse lymphoma assay at c oncentrations up to 400 
mcg/mL without S9 metabolic activation and up to 300 mcg/mL in the presence of S9.  
UT-15C was tested in vivo  in the rat micronucleus assay, which aimed to evaluate the potential of UT -15C 
to increase the incidence of micronucleated polychromatic erythrocytes in bone marrow of rats.  The 
results of the assay indicated that oral administration of UT -15C at total doses up to and including a dose 
of 50 mg treprostinil (equivalent to 63.4  mg UT -15C/kg) did not induce a significant increas e in the 
incidence of micronucleated polychromatic erythrocytes in either male or female SD rats.  Mortality 
observed at the high dose indicates systemic exposure of animals to the test article.  Based upon these 
findings, treprostinil diethanolamine (UT -15C) was concluded to be negative in the rat micronucleus 
assay.  
 
Segment I (rat) and Segment II (rat and rabbit) reproductive and developmental toxicology studies have 
also been conducted. No adverse effects for fetal viability / growth and fetal developme nt (teratogenicity) 
were seen in rats at or below 20 mg/kg/day or rabbits at or below 0.5 mg/kg/day.  At high doses, there 
were teratogenic effects of UT -15C observed when administered to rabbits.  Findings included increased 
fetal incidence of external, s oft tissue, and skeletal malformations.  Additionally, a Segment III 
reproductive and developmental toxicology study has been conducted in female rats.  F0 female rats 
receiving 10  mg/kg/day had decreased food consumption and body weights during gestation,  increased 
duration of gestation, had slight decreases in the viability and number of pups per litter, and pups with 
decreased mean neonatal body weights.  F1 pups of females that received 20  mg/kg/day had 
abnormalities in physical development (development al landmarks), reflex development, exploratory 
behavior, learning and memory, and sexual maturation.  
 
A six month carcinogenicity study in hemizygous Tg.rasH2 mice administered UT -15C at daily oral doses 
of 3, 7.5, 15 mg/kg and 5, 10, 20 mg/kg in females a nd males, respectively, for 26 -weeks did not increase 
the incidence of neoplastic lesions.   A two year rat carcinogenicity study is ongoing . 
 
Studies have been conducted by the United States National Toxicology Program (NTP) to determine 
whether diethanola mine by itself (without treprostinil or any other drug) causes cancer.  Two years of 
topical administration of diethanolamine to mice produced an increased incidence (compared to a control 
group) of malignant liver tumors in males and females, as well as a n increased incidence of malignant 
kidney tumors in males.  Doses used in this study were approximately 720 to 2,900 times higher (based 
on mg/m2 dosing) than the proposed starting doses for the UT -15C clinical studies.  However, in 
transgenic mice and rat s, topical administration of diethanolamine for twenty weeks and two years, 
respectively, was not associated with the development of any cancers.  The relevance of the mouse 
tumor findings to humans is currently unknown.  Diethanolamine is listed on the FD A database of inactive 
ingredients for a number of approved drug products with no apparent safety concerns.  
 
A GLP cardiovascular safety pharmacology study (Study 1259DU16.003) to evaluate diethanolamine 
effects, independent of treprostinil, on cardiovascu lar function in telemetered dogs has been  conducted.  
Since there are 0.269 grams of diethanolamine per each gram of treprostinil in UT -15C, for this study, 
doses of diethanolamine were selected that were similar or higher than the amount of diethanolamine  
contained in the doses of UT -15C assessed in the UT -15C cardiovascular safety pharmacology study 
(Study 1259DU16.002).  Doses of 0, 2, 3 and 4 mg/kg/day of diethanolamine (equivalent to the amount of 
diethanolamine administered with 7, 11, and 15 mg/kg/da y of treprostinil, the free acid of UT -15C), were 
selected to be administered to each of one group of four telemetered male dogs.  Oral administration of 
diethanolamine at doses up to 2  mg/kg/dose twice daily (4 mg/kg/day) to male beagle dogs was not 
assoc iated with any definitive changes in arterial pressure, heart rate or electrocardiogram parameters.  
In addition, no abnormal clinical signs were noted in the animals dosed with the vehicle or with any of the 
doses of diethanolamine.  
Protocol Number TDE -PH-304 Amendment 5  Confidential  
United Therapeutics Corporation  
Final  Version Dated 20 March 2013  11 1.2.2  UT-15C SR  Clinic al Pharmacology  
In solution, both treprostinil sodium and treprostinil diethanolamine are disassociated from their respective 
salt counter -ions and exist as the freely ionized form of treprostinil.  As a result, the bioactive form present 
in the bloodstrea m is identical irrespective of the selection of the counter -ion. Given this premise, the 
development of this new diethanolamine salt of treprostinil is expected to retain the bioactivity and safety 
profile of treprostinil sodium.  
 
The most frequent AEs ass ociated with Remodulin in clinical trials of patients with PAH were related to 
the pharmacological properties of Remodulin and were generally not serious.  These prostacyclin -related 
AEs included diarrhea, headache, and nausea.  Remodulin has not been asso ciated with any significant 
changes in laboratory parameters or end -organ toxicity.  The safety profile noted in the open label 
extension study, with much longer durations of exposure and a larger, more diverse patient population, 
was consistent with the p rofile noted in the controlled trials.  To date, well over 10,000 subjects and 
patients have been exposed to Remodulin.  This number includes patients who have received single 
administration, to patients receiving continuous infusion for greater than 10 ye ars. 
 
UT-15C has been administered to approximately 1,600 subjects in phase I -III clinical trials.  UT -15C 
doses of up to 3 mg twice daily (BID) have been administered to healthy volunteers and patients with 
PAH have received up to 22 mg BID in the ongoing  phase III development program. The longest 
individual exposure is now greater than  five years.  
 
The absolute bioavailability of the UT -15C 1 mg tablet is 17% compared with IV Remodulin.  Following 
administration, treprostinil diethanolamine is widely dist ributed.  Treprostinil is approximately 96% protein 
bound with no effect on warfarin or digoxin displacement.  Pharmacokinetic data (area under the curve; 
AUC) indicate that Day 1 pharmacokinetic data are predictive of Day 13 and linearity was observed in 
plasma exposure comparing 1  mg and 2  mg doses in healthy volunteers.  Food, particularly a high calorie 
meal, has been observed to increase absorption and prolong the systemic exposure to treprostinil, 
contributing to the desired pharmacokinetic profile.  Consistent with  in vitro studies, clinical studies 
assessing the impact of induction and inhibition of the cytochrome P450 (CYP) 2C8 and CYP 2C9 
metabolic pathways on treprostinil diethanolamine indicate that CYP 2C8 appears to be of major 
importance and C YP 2C9 of minor importance to in vivo  metabolism of UT -15C in humans.  
A comprehensive description of UT -15C (treprostinil diethanolamine), including the pharmacology, 
toxicology, and clinical studies completed to date may be found in the most recent Invest igators’ 
Brochure.  
 
To date, the majority of UT -15C clinical  studies have been conducted with twice daily dosing.  In an 
attempt to understand the pharmacokinetics of three times daily dosing (TID) a study was conducted in 
healthy volunteers.  In this open -label, single -center study 19 healthy subjects received 0.5 mg TID for 7 
days.  On the morning of Day 1 subjects received a single 0.5 mg dose, on Days 2 -7 the subjects 
received TID dosing of 0.5 mg (approximately 8AM, 2PM, and 8PM)  administered immediate ly following a 
meal. On the morning of Day 8, the subjects received a final dose of 0.5 mg.  
 
Intensive 24 hour PK sampling occurred following the 8AM doses on Days 1, 7 and 8. Trough samples 
were collected prior to the morning (8 AM) and evening (8PM) dose s on Days 4, 5 and 6.   
Nineteen subjects (9F: 10M) with a mean age of 35.2 years (range: 20 -54) were enrolled.  On Day 1 the 
mean (+/ - SD) maximum plasma concentration (Cmax) of treprostinil was 0.574 +/ - 0.22 ng/mL, occurring 
at a median time of 4 hours (range: 2 -6 hrs).  In comparison, the Day 8 mean (+/ - SD)  Cmax was 0.615 
+/- 0.32 ng/mL, occurring at a median time of 4 hours (range: 1 -6 hrs). [Figure 1]    
Protocol Number TDE -PH-304 Amendment 5  Confidential  
United Therapeutics Corporation  
Final  Version Dated 20 March 2013  13 1.2.3  Remodulin Experience  
Remodulin (treprostinil sodium) Injection is a sterile solution of treprostinil sodium formulated for 
subcutaneous or intravenous administration using an ambulatory infusion pump.  The toxicity profile of 
treprostinil delivered by continuous sub cutaneous infusion has been extensively evaluated.  The studies 
conducted include the complete International Conference on Harmonisation (ICH) battery of genetic 
toxicology studies; acute, single -dose, intravenous and oral toxicity studies in rats and mice ; acute, 
single -dose, subcutaneous toxicity studies in rats and dogs; repeat dose, continuous subcutaneous 
infusion toxicity studies up to 6 months in duration in rats and dogs; and reproductive toxicity studies in 
rats (fertility, teratology and pre/postn atal) and rabbits (teratology).  
 
 
The clinical development of subcutaneous Remodulin included two international, placebo -controlled, 
pivotal studies (13 countries, 40 centers).  These two studies were identical in design and together 
enrolled 470 patients with PAH.  Patients receiving Remodulin had clinically significant improvements in 
exercise tolerance (both distance walked and associated dyspnea), symptoms of PAH, physician -based 
dyspnea -fatigue rating, hemodynamic variables, and quality of life (physic al domain) compared to patients 
receiving placebo treatment.  Open -label efficacy data collected by the clinical centers indicate that the 
clinical benefits of Remodulin are maintained with long -term treatment.  
 
The most frequent adverse events (AEs) assoc iated with Remodulin therapy were related to the 
pharmacological properties of Remodulin and were generally not serious.  These prostacyclin -related AEs 
fell into two categories: those related to the local prostaglandin action at the subcutaneous infusion site 
(e.g., infusion site pain and reaction), and those related to systemic effects that are characteristic of 
prostacyclin (e.g., diarrhea, headache, nausea).  Localized subcutaneous infusion site pain and reaction 
were common (85% of Remodulin -treated pa tients), but were generally manageable, typically resulted in 
withdrawal of treatment in a low percentage of patients (10 -15%), did not limit increases in dose, and 
tended to improve with time on therapy.  Remodulin was not associated with any significant changes in 
laboratory parameters or end -organ toxicity.  The safety profile noted in the open -label extension study, 
with much longer durations of exposure and a larger more diverse patient population, was consistent with 
the profile noted in the controlle d trials.  Thus, Remodulin was shown to be a safe and effective treatment 
option for patients with PAH.  
 
To date, well over 10,000 patients/subjects have been exposed to Remodulin from single administration 
to patients receiving continuous infusion of Remo dulin for greater than 10 years.  The Remodulin 
(treprostinil sodium) Injection approved product label should be reviewed for additional details on the 
results of studies undertaken during the development of Remodulin.  
 
Although Remodulin is an effective a gent given by subcutaneous or intravenous delivery, these forms of 
administration have patient convenience limitations, including the need for an ambulatory infusion device 
and pain at the site of infusion associated with subcutaneous delivery.  Thus, an o rally available 
formulation of treprostinil would be of tremendous benefit.  However, the sodium salt of treprostinil (i.e., 
Remodulin) is not an appropriate candidate to develop as a solid -dose oral compound.  A more desirable 
salt of treprostinil (dietha nolamine) is therefore being investigated.  
1.3 Rationale for Development of Study Drug in Disease/Condition  
Prostacyclin (PGI 2) is a potent vasodilator and inhibitor of platelet aggregation that is produced by 
vascular endothelium.  A synthetic salt of pro stacyclin ( i.e.Flolan®) was developed and has demonstrated 
the clinical utility of prostacyclin in the treatment of pulmonary hypertension and other vascular diseases.  
Unfortunately, due to its very short half -life and chemical instability, Flolan must be  continuously infused 
by intravenous delivery.  Various analogues have been developed that have overcome some of these 
limitations, but the few orally active agents have remained limited by their short half -life and poor 
solubility.  Remodulin (treprostin il sodium) is a chemically stable, longer acting analogue that has shown 
clinical effectiveness when administered by the continuous subcutaneous and intravenous routes. Recent 
data indicate that a new salt form of treprostinil, diethanolamine, may be deliv ered by the oral route.  It is 
expected that an oral formulation of treprostinil will not only allow patients suffering from PAH to benefit 
Protocol Number TDE -PH-304 Amendment 5  Confidential  
United Therapeutics Corporation  
Final  Version Dated 20 March 2013  14 from the simplicity of an oral dosage form but may also facilitate the treatment of either previously 
untreated cond itions or improve the treatment of conditions that are not adequately controlled with current 
therapies.  
  
1.4 Clinical Hypothesis  
 
This open -label study will evaluate the safety of continued therapy with UT-15C SR  in subject s who 
completed assess ments in Prot ocol TDE-PH-202, TDE-PH-203, TDE -PH-205, TDE-PH-301, TDE-PH-
302, TDE -PH-308, or any other study evaluating UT -15C SR in patients with PAH .  The study will also 
provide information about long -term dosing patterns.  Finally, a 6-Minute Walk  Test with Borg Dy spnea 
Score to be conducted after subject s have completed one year of treatment with UT-15C SR  will provide 
information about the efficacy of long -term treatment.  
 
With Amendment 5, subjects will have the option of modifying their dos ing regimen  from BID t o TID. The 
intention of  the dosing modification  from BID to TID is to deliver a  more sustained plasma concentration  
of treprostinil thereby providing  systemic exposure to drug that resembles the approved parenteral  
product, Remodulin, while reducing  the oc currence and/or severity of  prostacyclin -related  adverse events 
previously associated  with the twice daily regimen.   
 
The transition from BID to TID dosing should be made at the discretion of the investigator taking into 
account  the subjects current disea se state and tolerability of UT -15C.  
 
2 STUDY OBJECTIVES AND ENDPOINTS  
2.1   Study Objective s 
The objectives of this study are to:  
• Provide, or continue to provide, UT-15C SR  for eligible subject s who particip ated in protocols TDE-
PH-202, TDE-PH-203, TDE -PH-205, TDE-PH-301, TDE-PH-302, TDE-PH-308 or additional  UT-15C 
SR clinical protocol s.  
• Assess the long -term safety of UT-15C SR  in these subject s through assessment of adverse events 
and laboratory parameters .  
• Assess the effect of continued therapy with UT-15C SR  on exercise capacity after one year of 
treatment.  
2.2 Study Endpoints  
The safety endpoints are as follows:  
• Adverse events  
• Clinical laboratory parameters  
PAH concomitant medications also will be documented.  
Efficacy will be assessed by a 6-Minute Walk  Test and Borg Dyspnea Score  to be conducted after each 
subject  has completed one year of therapy with UT-15C SR . 
3 EXPERIMENTAL PLAN  
3.1   Study Design  
 
Protocol Number TDE -PH-304 Amendment 5  Confidential  
United Therapeutics Corporation  
Final  Version Dated 20 March 2013  15 This is an open -label study.  Each subject ’s visit schedule will allow assessments after defined perio ds of 
exposure to UT-15C SR  (3, 6, 12, 24 and 36 months total exposure).   The study will continue with yearly 
visits beyond 36 months until either UT-15C SR is approved by the appropriate regulatory authorities  or 
the study is discontinued by the sponsor.  Therefore, the actual date of each visit will be determined by 
the date on which the subject  first received UT-15C SR  (e.g., the date of study drug ini tiation in TDE -PH-
301, TDE-PH-302, or TDE -PH-308 for subject s who were randomized to active therapy in t hose trials, 
and the date of UT-15C SR  initiation in this study for subject s who were randomized to placebo in the 
previous controlled trial ). Note that the TDE -PH-202, TDE-PH-203, TDE -PH-205 studies are open -label 
design and therefore will follow the regi men for subjects receiving UT -15C SR .  
 
Subjects enrolled from the TDE -PH-202 study  who were in Dose Groups 1 or 2 and permanently 
discontinued treatment may enter the study if they undergo all premature termination assessments prior 
to discontinuing study  drug and complete all remaining scheduled study visits and assessments (with the 
exception of the hemodynamic measurements) through Week 12. These subjects should follow the same 
procedures as subjects who received placebo in the previous study and will b egin on a dose of 0.25mg  
BID. 
 
Subject s randomized to UT-15C SR  in Protocol TDE -PH-301, TDE-PH-302, or TDE -PH-308 will complete 
visits 2 -5 and yearly visits thereafter , while subject s randomized to placebo in Protocol TDE -PH-301, 
TDE-PH-302, or TDE -PH-308 will complete visits 1 -5 and yearly visits thereafter .  A 6-Minute Walk  test 
and Borg Dyspnea Score will be conducted at the visit occurring 12 months after the subject ’s initial 
exposure to UT-15C SR . 
 
3.2 Overall Schedule of Times and Events  
 
The overall sch edule of Time and Events is shown in Table 3.2.  Note that the timing of each visit 
depends upon when the subject  first received UT-15C SR  (e.g. whether the subject  was assigned to 
active or placebo tre atment in Protocol TDE -PH-301, TDE-PH-302, or TDE -PH-308).  Subjects receiving 
placebo in the previous study , or subjects enrolled from the TDE -PH-202 stu dy who are beginning a dose 
of 0.25mg BID,  must be contacted weekly by telephone (at a minimum) during the first 12 weeks of the 
open -label study to ensure subject safety.  More specifically, these calls should assess study drug dose 
titration needs, potential adverse events, concomitant medication usage and PAH signs and symptoms .  
Monthly telephone calls  (at a minimum)  must be conducted for all subjects act ively participating in TDE -
PH-304, regardless of study drug  allocation  (UT-15C SR or placebo)  in the previous study, to assess 
dose titration needs, potential adverse events, concomitant medication usage and PAH signs and 
symptoms.   In addition to the sche duled study visits, all subjects must be seen in the clinic no less than 
once every six months for routine standard of care medical evaluation .  
 
Subjects enrolling from the TDE -PH-203 an d TDE -PH-205 studies will transition  on the same dose they 
were recei ving at the end of the study. Study visits for the TDE -PH-304 protocol will be based on the date 
the subject first received active UT -15C in their respective preceding study.  
Protocol Number TDE -PH-304 Amendment 5  Confidential  
United Therapeutics Corporation  
Final  Version Dated 20 March 2013  16 Table 3.2.  Time and Events  
 Visit  4,5,6,7 
Assessment  Visit 0 -1 
(Weeks 1 -12) 3 1 2 3 4 5+8 EXIT9  
Adverse Events  X X X X X X X 
PAH Concomitant Medications  X X X X X X X 
Concomitant Medications  X X X X X X X 
6-Minute Walk Test/Borg Dyspnea Score 1    X    
Clinical Laboratory Parameters 2  X X X X X X 
Drug Accountability/Complia nce X X X X X X X 
1 6-Minute Walk  Test/ Borg Dyspnea  Score  as described in Appendix A.  conducted 3 to 6 hours after the 
morning dose of UT -15C SR.  
2 Laboratories  to be colle cted are described in Appendix B . 
3 Weekly t elephone calls  (at a minimum) required  during Weeks 1 -12 for subjects randomi zed to placebo in 
TDE-PH-301, 302, or 308 to assess dose titration needs, potential adverse events, concomitant medication 
usage and PAH signs and symptoms . Also applies to subjects enrolled from the TDE -PH-202 study w ho are 
beginning a dose of 0.25mg BID.  
4 Visit  windows  are ± 1  month from the scheduled number of months from  first exposure to UT-15C SR , 
except for Visit 1, which is ± 2 weeks.  
5 VISIT 1  – Only for subject s randomized to placebo in TDE -PH-301, 302, or 3 08; 3 months after subject ’s first 
exposure to UT -15C.  Also applies to subjects enrolled from the TDE -PH-202 study who are beginning a 
dose of 0.25mg BID.  
VISIT 2  – 6 months after subject ’s first exposure to UT-15C SR . 
VISIT 3  – 12 months after subject ’s first exposure to UT-15C SR . 
VISIT 4  – 24 months after subject ’s first exposure to UT-15C SR . 
VISIT 5  – 36 months  after subject ’s first exposure to UT-15C SR . 
6 Weekly telephone call  required  for 4 weeks  for all subjects who transition from a BID to TID re gimen to 
assess dose titration needs, potential adverse events, concomitant medication usage and PAH signs and 
symptoms . 
7 Monthly telephone calls  (at a minimum) required for all subjects participating in TDE -PH-304 to assess 
dose titration needs, potentia l adverse events, concomitant medication usage and PAH signs and 
symptoms. 
8 Visits beyond Visit 5  will occur yearly until either the drug receives regulatory approval in a particular 
region or the sponsor discontinues the study.  Assessments after visit 5 will include adverse events, PAH 
concomitant medications, concomitant medications, clinical laboratories, and compliance/drug 
accountability.  
9  EXIT  – If the subject  discontinues  from the study  between scheduled visits , every effort should be made to 
obtain the exit assessments just prior to termination from the study . 
3.3 Clinical Assessments  
3.3.1  Efficacy  
A 6-Minute Walk  Test with Borg Dyspnea Score  (described in Appendix A)  will be conducted at Visit 3, 12 
months from the subject ’s first exposure to UT-15C SR .  The 6 -Minute Walk Test should be conducted 
approximately 3 to 6 hours after the morning dose of UT -15C SR.  
3.3.2  Safety  
3.3.2.1  Clinical Laboratory Assessments  
Clinical  laboratory parameters  will be assessed at each study visit .  Laboratories to  be assessed at the 
study vi sits are listed  in Appendix B . 
3.3.2. 2  Adverse Event Assessment  
Protocol Number TDE -PH-304 Amendment 5  Confidential  
United Therapeutics Corporation  
Final  Version Dated 20 March 2013  17 Adverse event reporting instructi ons for protocols TDE-PH-202, TDE-PH-203, TDE -PH-205, TDE-PH-
301, TDE-PH-302, and TDE -PH-308 will be followed in the open -label st udy.  Adverse events will be 
reported continuously , as in protocols  TDE-PH-202, TDE-PH-301, TDE-PH-302, and TDE -PH-308 and 
documented on the Case Report Form (CRF).  Any AEs that were ongoing at the time of dischar ge from 
protocols TDE-PH-202, TDE-PH-203, TDE-PH-205,TDE-PH-301, TDE-PH-302, or TDE -PH-308 should 
be recorded as a part of the medical history in the open -label study.  Section 9 and Appendix C provide 
the guidelines and definitions for recording of AEs. 
 
For subjects transitioning from a BID to T ID regimen, additional adverse event information will be 
collected via weekly phone contact  for at least  four weeks from the date of transition.  
 
3.3.2.3 . Concomitant  Medications  
 
In this open -label study, there are no restrictions on concomitant medicati ons, with the exception of the 
addition of prostanoid therapy. If chronic  parenteral prostanoid therapy is added for the treatment of 
worsening PAH, the subject will be discontinued from the study. Short term, parenteral prostanoid therapy 
may be initiated  if required (e.g., the patient is  temporarily  unable to take oral medications). If prostanoid 
therapy is initiated for any other reason than worsening PAH, eligibility for continued participation in this 
study will need to be reviewed by the Medical Monit or on a case by case basis. For subjects enrolling into 
TDE-PH-304 from the TDE -PH-203 study  continued chronic use of inhaled treprostinil (Tyvaso®) is 
acceptable .  
 
ERAs and PDE -5 inhibitors may be added or withdrawn  at any time.  Concomitant PDE -5 inhibit ors, ERAs , 
and other medications related to the subject’s treatment will be collected at each study visit and recorded 
in the CRF . 
 
 
3.4 Number of Centers  
The study will be an international, multi -center study with approximately 118 centers participating.  All 
centers partic ipating in protocols TDE-PH-202, TDE-PH-301, TDE-PH-302, and/or TDE -PH-308 or other 
UT-15C SR clinical protocols  will participate in this open -label study.  
3.5 Number of Subjects  
Approximately 900 subjects will be enrolled across all sit es participating in either TDE-PH-202, TDE-PH-
203, TDE -PH-205, TDE-PH-301, TDE-PH-302, or TDE -PH-308.  Additional subjects may be enrolled from 
other clinical protocols evaluating UT -15C SR in subjects with PAH.   All subjects successfully completing 
all as sessments i n either protocol TDE-PH-202, TDE -PH-203, TDE -PH-205, TDE-PH-301, TDE-PH-302, 
TDE-PH-308 or other UT -15C SR clinical protocols  are eligible for participation .   
 
Subjects randomized into Dose Group 1 or Dose Group 2  in the TDE -PH-202 study  who p ermanently 
discontinue study drug during the 12 -week Treatment Phase due to clinical worsening are eligible for 
entry into the TDE -PH-304 if they undergo all premature termination assessments prior to discontinuing 
study drug and complete all remaining sch eduled study visits and assessments (with the exception of the 
hemodynamic measurements) through Week 12.  Such subjects should start treatment with UT -15C in 
the open -label study at 0.25 mg BID.    
3.6 Estimated Study Duration  
The estimated study duration for each subject  is at least  36 months  from the point of transit ion from 
protocol TDE-PH-202, TDE -PH-203, TDE -PH-205, TDE-PH-301, TDE-PH-302, or TDE -PH-308 to the 
end of the open -label study.   The study will continue until either UT-15C SR receives regulat ory approval 
in a region or the study is discontinued by the sponsor.  
Protocol Number TDE -PH-304 Amendment 5  Confidential  
United Therapeutics Corporation  
Final  Version Dated 20 March 2013  18 4 SUBJECT ELIGIBILITY  
4.1 Subject Inclusion Criteria  
A subject is eligible for inclusion in this study if all of the following criteria apply:  
1. The subject has remained on study drug a nd completed all assessments during the Treatment 
Phase of the previous stud y (TDE-PH-202, TDE-PH-203, TDE -PH-205,TDE-PH-301, TDE-PH-
302, or TDE -PH-308 (or other studies evaluating PAH) )  
OR 
 The subject permanently discontinued study drug during the Treat ment Phase of th e previous 
study (TDE -PH-301, TDE -PH-302, or TDE -PH-308) due to clinical worsening, completed 
premature termination assessments prior to discontinuing study drug, completed all remaining 
scheduled study visits AND received placebo  during th e Treatment Phase of the previous study 
(TDE-PH-301, TDE -PH-302, or TDE -PH-308).  
OR 
The subject was randomized into Dose Group 1 or Dose Group 2 in the TDE -PH-202, 
permanently discontinue d study drug during the 12 -week Treatment Phase due to clinical 
wors ening , completed  all premature termination assessments prior to discontinuing study drug 
and complete d all remaining scheduled study visits and assessments (with the exception of the 
hemodynamic measurements) through Week 12.  Such subjects should start tr eatment with UT -
15C in the open -label study at 0.25 mg BID .   
 
2.   The subject voluntarily gives informed consent to participate in the study.  
 
3.  Women of child bearing potential include any female who has experienced menarche and who 
has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or 
bilateral oophorectomy) or is not postmenopausal [defined as amenorrhea for at least 12 
consecutive months].  Sexually active women of childbearing potential must us e two effectiv e 
forms of  contraception during the length of th e study.  Medically  acceptable forms of effective 
contraception include:  (1) approved hormonal contraceptives (such as birth control pills), (2) 
barrier methods (such as a condom or diaphragm) used with a spe rmicide, (3) an intrauterine 
device (IUD),  (4) partner vasectomy , or (5) abstinence. Males  participating in the study must use 
a condom during the length of the study, and for at least 48 hours after discontinuing study 
medication.  
 
4.2 Subject Exclusion C riteria  
 
1. The subject permanently discontinued study drug during the previous study ( TDE-PH-202, TDE-
PH-203, TDE -PH-205, TDE-PH-301, TDE -PH-302, or TDE -PH-308) due to treatment related 
adverse events.  
 
2. The subject permanently discontinued study drug d uring the Treatment Phase of the previous 
study ( TDE-PH-202, TDE-PH-203, TDE -PH-205, TDE-PH-301, TDE -PH-302, or TDE -PH-308) 
due to clinical worsening (as defined in those study protocols) and did not undergo premature 
termination assessments prior to disco ntinuing study drug, and/or did not complete all remaining 
study visits through the final scheduled visit.  
 
3. The subject permanently discontinued study drug during the Treatment Phase of the previous 
study ( TDE-PH-301, TDE -PH-302, or TDE -PH-308) due to c linical worsening, completed 
premature termination assessments prior to discontinuing study drug, completed all remaining 
scheduled study visits AND received UT -15C SR  during the Treatment Phase of the previous 
study ( TDE-PH-301, TDE -PH-302, or TDE -PH-308). 
 
Subjects enrolled in the TDE -PH-202 study who were randomized into the iMTD group who 
clinically worsen may not participate.  Subjects who permanently discontinue study drug during 
Protocol Number TDE -PH-304 Amendment 5  Confidential  
United Therapeutics Corporation  
Final  Version Dated 20 March 2013  19 the 12 -week Treatment Phase due to treatment related adverse events are not eligib le even if 
they complete all remaining scheduled study visits.  Subjects who permanently discontinue study 
drug during the 12 -week Treatment Phase and do not undergo premature termination 
assessments prior to discontinuing study drug and/or who d o not complete all remaining study 
visits through the Wee k 12 visit are also not eligible .   
 
 
4. The subject must not have developed any concurrent illness or condition during the conduct of 
the previous study, including but not restricted to, sleep apnea , chronic renal insufficiency, 
anemia, uncontrolled systemic hypertension or left sided heart disease, unless their physician 
feels that entry into this study would not be detrimental to their overall health.  
5 SUBJECT ENROLLMENT  
5.1 Treatment Assignment  
All subjects will receive UT-15C SR  during the open -label study.  
5.2 Randomization  
This study is not randomized.  
5.3 Blinding  
This study is not blinded.  
6 DRUGS AND DOSING  
6.1 Drug Dosage, Administration and Schedule  
UT-15C SR tablets will be provided as 0.25, 0.5, 1, and 2.5  mg tablet strengths.  They may also be 
provided as 0.125  mg strength , if available.  The 0.125, 0.25, 0.5, 1, and 2.5 mg  tablets are colored blue, 
green, white, yellow, and pink, respectively.  
 
For subject s who were randomized to placeb o in protocol s TDE-PH-301, TDE-PH-302, or TDE -PH-308, 
dosing of UT-15C SR  will be initiated and optimized as in the previous protocol, including all safety 
monitoring  including periodic telephone contacts .  That is, the first dose of UT-15C SR  (0.25 mg) sh ould 
be taken by the subject immediately following  (~ 10 minutes)  a meal while at the study site.  The subject 
should remain close to the study site for approximately 3 to 6 hours for periodic observation and 
monitoring of possible AEs.   
 
Subjects who wer e randomized to UT -15C SR , or were receiving active  therapy in the previous trial will 
begin open -label therapy at the same dose  and regimen  (e.g. BID or TID)  they were receiving at the final  
visit in the previous trial, and subsequent dose adjustments wil l be made based on symptoms of PAH and 
AEs.  
 
With Amendment 5, subjects may now receive UT -15C either twice (BID) or three (TID) time daily. The 
decision to transition subjects from BID to TID is up to the discretion of the principal investigator, and not 
a requirement of the protocol.  
 
The dose of UT -15C SR at the time the subject is discharged from each study visit should be recorded on 
the CRF.  
 
6.1.1   T wice Daily  Dosing Regimen  
 
Protocol Number TDE -PH-304 Amendment 5  Confidential  
United Therapeutics Corporation  
Final  Version Dated 20 March 2013  20 The next dose of study drug should be taken the following morning.  At th is time oral dosing of UT-15C 
SR will be initiated at 0.25 mg twice daily  (every 12 hours +/ - 1 hour)  immediately following (~10 minutes) 
breakfast and dinner.  Subjects must be instructed to take the appropriate amount of 0.25, 0.5, 1, and/or 
2.5 mg table ts based upon their given dose.  In general, the dose of study drug should be increased  in 
0.25 to 0.5 mg increments  every 3 days, in the absence of dose -limiting drug -related side effects, to 
ensure the subject receives the optimum clinical dose throughou t the study.  The 0. 125 mg strength, if 
available, may be used throughout the study if a 0.25 mg dose increase is not tolerated and an 
intermediate dose is required .  Dose changes should be conducted under appropriate medical 
supervision in consultation wi th the study site.  
 
6.1.2   Transition from Twice  to Three Times daily Dosing  
 
For subjects enrolled in the TDE-PH-304 study who are receiving UT -15C twice daily, dosing frequency 
may be tra nsitioned from BID to TID .  For applicable subjects, it is recomm ended to reduce the total daily 
dose administered during BID dosing by approximately 25% and divide the total daily dose into a TID 
regimen using the appropriate  tablet strength (s).  Please see Table  6-1 below for examples of 
transitioning from BID dosing to TID dosing.   However, dose modification should occur in accordance 
with investigator judgment.  
Table  6-1  Example Transition from Twice Daily to Three Times Daily Dosing of  
UT-15C 
BID Dosing Regimen  Total Daily  
Dose with BID 
Dosing  Total Daily 
Dose with 
BID Dosing 
Reduced by 
25% TID Dosing 
Regimen  Total Daily 
Dose with 
TID Dosing  
3 mg BID  6 mg  4.5 mg  1.5 mg TID  4.5 mg  
5 mg qAM; 5.25 mg qPM  10.25 mg  7.6875 mg  2.5 mg TID  7.5 mg  
6 mg BID  12 mg  9 mg  3 mg TID  9 mg  
6.5 mg qAM; 6.625 mg qPM  13.125 mg  9.844 mg  3.25 mg TID  9.75 mg  
10 mg BID  20 mg  15 mg  5 mg TID  15 mg  
11 mg qAM; 11.5 mg qPM  22.5 mg  16.875 mg  5.5 mg TID  16.5 mg  
13 mg BID  26 mg  19.5 mg  6.5 mg TID  19.5 mg  
17.125 mg qAM; 17.25 mg qPM  34.375 mg  25.781 mg 8.5 mg TID  25.5 mg  
 
Dose changes should be conducted under appropriate medical supervision in consultation with the study 
site.  If dose titration is considered appropriate, site personnel will instruct the subject to modify their 
dose; dose changes wi ll be recorded in source documentation  and CRF by site personnel.   
 
6.1.3   Three Times ( TID) Daily  Dosing Regimen  
 
For subjects entering the TDE -PH-304 study receiving a TID dosing  regimen  (e.g. TDE -PH-205), or for 
those subjects transitioning from BID t o TID dosing, the dosing regimen should be managed as follows:  
• TID (every 6 -8 hours) with food  
• Increases should occur in increments of 0.125 or 0.25 mg TID every 3 days.  
 
In general, the dose of study drug should be increased in 0.125 to 0.25 mg increment s every 3 days, in 
the absence of dose -limiting drug -related side effects, to ensure the subject receives the optimum clinical 
dose throughout the study.  The 0.125 mg strength, if available, may be used throughout the study if a 
Protocol Number TDE -PH-304 Amendment 5  Confidential  
United Therapeutics Corporation  
Final  Version Dated 20 March 2013  21 0.25 mg dose increase is n ot tolerated and an intermediate dose is required.  Dose changes should be 
conducted under appropriate medical supervision in consultation with the study site.  
6.1.4   Dosing of Study Medication in Relation to Meal s 
Subjects should take study drug approxim ately every 12 hours (+/ - 1 hour) for BID dosing and every 6 – 8 
hours for TID dosing , with approximately 240 mL (8 ounces) of water or other beverage (e.g. juice, milk, 
soda, etc.) immediately after (~ 10 minutes) consuming food (approximately 250 calorie s). 
Subjects should be instructed to be careful not to break, chew, or disrupt the integrity of the tablet as this 
will result in inappropriate delivery of the active ingredient.  If the tablet is inadvertently damaged during 
administration, the subject sh ould contact site personnel in order to be monitored for the onset of 
symptoms due to possible overdose.  
6.2 Compliance  
At each visit, t he Investigator or designee will evaluate the amount of UT-15C SR  provided to each 
subject and any returned medication ( as required for drug accountability purposes), and compare this 
accounting with the subject ’s dosing pattern to obtain an estimate of overall compliance.  Each subject 
will also be asked at each visit whether he or she is in compliance with dosing instruct ions.  If it is 
determined that a subject is not compliant with study drug then site personnel should re -educate the 
subject on proper dosing compliance.  Continued non -compliance may lead to discontinuation of the 
subject, after consultation between the Investigator and sponsor.  
7 EXPERIMENTAL PROCEDURES  
7.1 Open -Label Phase  
All values collected at the subject’s respective final visit in protocol TDE-PH-202 TDE-PH-203, TDE -PH-
205, TDE-PH-301 or TDE -PH-308 and TDE -PH-302 will serve as the baseline assessmen ts for the open -
label study.    
 
Subjects receiving placebo in the previous study must  be contacted weekly by telephone (at a minimum)  
during the first 12 weeks of the open -label study and, if necessary, brought in for clinic visits in the first 
several mo nths of the study to ensure subject safety.   This also applies to subjects enrolled from the 
TDE-PH-202 study (Dose Groups 1 or 2) who are beginning a dose of 0.25mg BID.  
 
Monthly telephone calls (at a minimum) must be conducted for all subjects actively participating in the 
open -label study , regardless of study drug  allocation (UT-15C SR or placebo) in the previous study.  
 
In addition to the scheduled study visits,  as listed below,  all subjects must be seen in the clinic no less 
than once every six months  for routine standard of care medical evaluation .  
 
Week ly telephone calls ( required Weeks 1 -12; only for subjects randomized to placebo in previous study) . 
This also applies to subjects enrolled from the TDE -PH-202 study (Dose Groups 1 or 2) who are 
begin ning a dose of 0.25mg BID.  
• Adverse events  
• PAH concomitant medications  
• Concomitant medications  
Drug accountability  / compliance  
Weekly telephone calls (required for 4 weeks for subjects who transition from BID to TID  dosing ) 
• Adverse Events  
• PAH concomitant medications  
• Concomitant medications  
• Drug accountability/compliance  
 
Protocol Number TDE -PH-304 Amendment 5  Confidential  
United Therapeutics Corporation  
Final  Version Dated 20 March 2013  22 Monthly telephone calls ( required for all subjects participating in  open -label study)  
• Adverse events  
• PAH concomitant medications  
• Concomitant medications  
• Drug accountability  / compliance  
 
Visit 1 (three months after first dose of UT-15C SR ; only for subjects randomized to placebo in previous 
study) . This also applies to subjects enrolled from the TDE -PH-202 study (Dose Groups 1 or 2) who are 
beginning a dose of 0.25mg BID.  
• Adverse events  
• PAH concomitant medications  
• Concomitant m edications  
• Clinical laboratories  
• Drug accountability /compliance  
 
Visit 2  (six months after first dose of UT-15C SR ) 
• Adverse events  
• PAH concomitant medications  
• Concomitant medications  
• Clinical laboratories  
• Drug accounta bility/compliance  
 
Visit 3  (12 months after first dose of UT-15C SR ) 
• Adverse events  
• PAH concomitant medications  
• Concomitant medications  
• Clinical laboratories  
• Drug accountability /compliance  
• 6-Minute walk test/borg dyspnea score 
 
Visit 4  (24 months after fir st dose of UT-15C SR ) 
• Adverse events  
• PAH concomitant medications  
• Concomitant medications  
• Clinical laboratories  
• Drug accountability /compliance  
 
Visit 5  (36 months after first dose of UT-15C SR ) 
• Adverse events  
• PAH concomitant medications  
• Concomitant medicati ons 
• Clinical laboratories  
• Drug accountability /compliance  
 
Yearly visits beyond 36 months  
• Adverse events  
• PAH concomitant medications  
• Concomitant medications  
• Clinical laboratories  
• Drug accountability/compliance  
 
Exit (premature discontinuation)  
• Adverse events 
• PAH concomitant medications  
Protocol Number TDE -PH-304 Amendment 5  Confidential  
United Therapeutics Corporation  
Final  Version Dated 20 March 2013  23 • Concomitant medications  
• Clinical laboratories  
• Drug accountability /compliance  
8 STUDY TERMINATION  
8.1 Subject Discontinuation  
A subject may voluntarily withdraw or be withdrawn from the study by the Investigator at any time f or 
reasons including, but not limited to, the following:  
• The subject wishes to withdraw from further participation.  
• A serious or life -threatening AE occurs or the Investigator considers that it is necessary to 
discontinue study drug to protect the safety o f the subject.  
• The subject deviated from the protocol.  
• The subject’s behavior is likely to undermine the validity of his/her results.  
• The subject becomes pregnant  
If a subject is discontinued prematurely, the Investigator must provide an explanation in th e CRF 
(Investigator’s Comment Log) and complete the End of Study Record for that subject.  If study drug has 
been administered, the Investigator should make every effort to perform all scheduled evaluations prior to 
discharge.  In the event that a subject discontinues prematurely due to an AE, the subject will be followed 
until the Investigator d etermines the AE has resolved, the AE is  no longer considered clinically significant , 
the subject is lost  to follow -up, or for 30 days  following discontinuation of UT-15C. 
8.2 Study Discontinuation  
The study may be stopped at any time if, in the opinion of the Investigator and/or sponsor, continuation of 
the study represents a serious medical risk to the subjects.  This may include, but is not limited to, the 
presenc e of serious, life -threatening, or fatal adverse events or adverse events that are unacceptable in 
nature, severity, or frequency.  The sponsor reserves the right to discontinue the study for any reason at 
any time.  In the event the sponsor discontinues th e study, an EXIT visit for each subject should be 
scheduled.  
8.3 Site Discontinuation  
The study may also be terminated at a given center if:  
• The Principal Investigator elects to discontinue the study  
• The Sponsor elects to discontinue the study at the site  
• U.S. FDA, European, or national regulations are not observed  
• The protocol is violated  
• Changes in personnel or facilities adversely affect performance of the study  
Protocol Number TDE -PH-304 Amendment 5  Confidential  
United Therapeutics Corporation  
Final  Version Dated 20 March 2013  24 9 ADVERSE EVENT REPORTING  
9.1 Definitions  
9.1.1 Adverse  Event  
An AE is any untoward medical experience occurring to a subject during a clinical trial whether or not it is 
related to the study drug.  An AE may include an intercurrent illness, injury, or any other concomitant 
impairment of the subject’s health, as well as abnormal laboratory findin gs if deemed to have clinical 
significance.  AEs may also include worsening of an existing symptom or condition or post -treatment 
events that occur as a result of protocol -mandated procedures.  
9.1.2 Serious  Adverse Event  
A serious adverse event (SAE) is a n AE occurring at any dose that results in any of the following 
outcomes:  
• Death  
• A life -threatening AE  
• Inpatient hospitalization or prolongation of existing hospitalization  
o Planned hospitalizations (e.g., admission for elective surgery or right heart cathet erization) do 
not qualify as SAE’s  
• A persistent or significant disability/incapacity  
• A congenital anomaly/birth defect  
In addition, important medical events that may not result in death, be life -threatening, or require 
hospitalization may be considered ser ious when, based upon appropriate medical judgment, they may 
jeopardize the subject and require medical/surgical intervention to prevent one of the outcomes listed 
above.  Examples of such medical events include allergic bronchospasm requiring intensive tr eatment in 
an emergency room or at home, blood dyscrasias or convulsions that do not result in hospitalization, or 
the development of drug dependency or drug abuse.   
Life-threatening means that the subject was, in the view of the Investigator, at immediat e risk of death 
from the event as it occurred.  It does not mean that the event, had it occurred in a more severe form, 
might have caused death.  
9.1.3 Expected  Adverse Event  
Adverse events associated with progression of PAH:  
An expected event that is rela ted to the progression of a subject’s PAH is defined in Appendix D, Part A.  
All events that occur during the course of the study that are included on this list and felt to be related to 
progression of disease by the Investigator should NOT be recorded as AEs in the CRF as the most 
relevant PAH symptoms will be evaluated and recorded as an efficacy endpoint and all other events will 
be captured as disease related events.  If the event is either serious or unusual with respect to intensity, 
frequency, or dur ation, OR there is a reasonable possibility that it may have been caused by study drug, it 
must  be recorded as an AE in the CRF.  
Adverse events known to be associated with treprostinil therapy:  
An expected AE for UT -15C is defined as any AE that is defined  in terms of nature, severity, or frequency 
in the current Investigators’ Brochure and in Appendix D, Part B.  When an adverse event may be 
attributed to the progression of pulmonary hypertension or UT -15C SR (e.g., listed in both Parts A and B) 
it must be  recorded as an AE in the CRF if the event is either serious or unusual with respect to intensity, 
frequency, or duration, OR there is a reasonable possibility that it may have been caused by study drug.  
Protocol Number TDE -PH-304 Amendment 5  Confidential  
United Therapeutics Corporation  
Final  Version Dated 20 March 2013  25 Expected events attributable to UT -15C (e.g., liste d in Part B only) must always be recorded as AEs in 
the CRF.  
If an event listed in Appendix D Part A or B occurs during the conduct of the trial, it will not give rise to 
submission of an expedited safety report despite being considered serious and possibl y attributable to the 
study drug, unless the United Therapeutics Medical Monitor, responsible for assessing the case 
considers it to be unusual (e.g., more severe than expected) and therefore reportable.  The data 
regarding such events will always be recor ded in the clinical study database, regardless of reportability.  
9.2 Documentation  of Adverse Events  
An AE or SAE occurring during the study must be documented in the subject’s source documents and on 
the appropriate CRF page.  Information relating to the AE such as onset and cessation date and times, 
intensity, seriousness, relationship to study drug, and outcome will also be documented in the CRF (see  
Appendix C  for definitions).  Where possible, AEs should be recorded using standard medical 
terminology.  If several signs or symptoms are clearly related to a medically defined diagnosis or 
syndrome, the diagnosis or syndrome should be recorded on the CRF page, not the individual signs and 
symptoms.  
All adverse events should be followed until resolution (or return to normal or baseline values), until they 
are judged by the Investigator to no longer be clinica lly significant, or for 30 days  following discontinuation 
of UT -15C.  All SAEs that occur during the study will be followed until resolution, death, or t he subject is 
lost to follow -up.  Supplemental measurements and/or evaluations may be necessary to fully investigate 
the nature and/or causality of an AE or SAE.  This may include additional laboratory tests, diagnostic 
procedures, or consultation with oth er healthcare professionals.  CRF pages should be updated with any 
new or additional information as appropriate.  
9.3 Reporting  Responsibilities of the Investigator  
All SAEs, regardless of expectedness or causality, must be reported to the Sponsor by fax  or email   
 
 within 24 hours of awareness.  A completed SAE report form along with any 
relevant hospital records and autopsy reports should be  faxed to the Drug Safety Department at United 
Therapeutics Corporation.  A follow -up SAE report form should be forwarded to the Drug Safety 
Department at United Therapeutics Corporation within 48 hours of the receipt of any new/updated 
information.  The I nvestigator must also promptly notify the Investigational Review Board (IRB) or Ethics 
Committee (EC) of the SAE, including any follow -up information according to the guidelines set forth by 
the IRB or EC.   
9.4 Safety  Reports  
In accordance with FDA, Europ ean, and national regulations, the Sponsor will notify the FDA, other 
competent authorities, and all participating investigators of any AE that is considered to be possibly 
attributable to study drug and is both serious and unexpected.  The Investigator mu st report these AEs to 
their IRB or EC in accordance with applicable national regulations and guidelines set forth by the IRB or 
EC.  If an event listed in Appendix D Part A or B occurs during the conduct of the trial, it will not give rise 
to submission o f an expedited safety report despite being considered serious and possibly attributable to 
the study drug, unless the United Therapeutics Medical Monitor, responsible for assessing the case 
considers it to be unusual (e.g., more severe than expected) and t herefore reportable.  The data 
regarding such events will always be recorded in the clinical study database, regardless of reportability.  
9.5 P regnancy  
If a study subject becomes pregnant during participation in this clinical study, site staff must notify the 
sponsor within 24 hours of learning of the pregnancy by completing the Pregnancy Report Form and 
either faxing or emailing this form to 
  Subjects who 

Protocol Number TDE -PH-304 Amendment 5  Confidential  
United Therapeutics Corporation  
Final  Version Dated 20 March 2013  26 become pregnant during the trial will be withdrawn from active participation in the trial and will discontinue 
study drug after an appropriate period of down -titration.   
 
United Therapeutics Global Drug Safe ty will follow up with the Investigator each trimester to ensure 
appropriate data are provided regarding the outcome of the pregnancy, and to ask the Investigator to 
update the Pregnancy Report Form.  Pregnancy only becomes an AE / SAE if there is an abnor mal 
outcome, a spontaneous abortion, a termination for medical reasons other than PAH, or a congenital 
anomaly in the offspring.  
 
10 DATA MANGEMENT AND STATISTICS  
Completed CRFs will be forwarded to United Therapeutics or its designee for processing.   A quality-
assured computerized database will be constructed. Data will be listed and also will be summarized either 
in tabular and/or graphical presentations.  
The safety of UT-15C SR  will be assessed using laboratory assessments and reports of adverse e vents .  
All reported adverse event s will be assigned M edDRA terms which will be listed and summarized 
according to intensity, seriousness and causality.  
Efficacy assessments ( 6-Minute Walk/Borg Dyspnea Score) may be compared to assessments in 
Protocols TDE-PH-202, TDE-PH-203, TDE -PH-205, TDE-PH-301, TDE-PH-302, TDE-PH-308, or TDE -
PH-304, as appropriate .  Doses of UT-15C SR  will be listed, summarized and analyzed for trends over 
time.  
11 PACKAGING AND FORMULATION  
11.1 Study Drug Content    
United Therapeutics will supply UT-15C SR  for administration in the study.  UT-15C SR tablets will be 
provided as 0.25, 0.5, 1, and 2.5  mg strengths and may also be provided as a 0.125 mg strength , if 
available. UT-15C SR  0.125 mg ( blue), 0.25 mg (green), 0.5 mg (white), 1 mg (yel low), and 2.5 mg ( pink) 
tablets  will be provided in child resistant bottles each containing  100 tablets , or in other appropriate 
packaging configurations as may be required as more experience with long -term dosing requirements is 
obtained.   
11.2 Study Dru g Labeling  
Each bottle and/or other packaging  (e.g., kits/cartons)  for UT-15C SR  will be labeled with at least the 
following information:  study drug, strength, quantity, manufacture date, lot number, sponsor name and 
address, and storage conditions.   
11.3 Study Drug Storage and Handling  
All study drug will be stored in accordance with label specified storage conditions .  UT-15C SR  should not 
be frozen or exposed to heat.   
Subjects should be instructed to return all study drug, including empt y bottles  or other containers , to the 
appropriate study personnel  for drug accountability and compliance assessments, as appropriate . 
11.4 Study Drug Supply and Return  
Study sites will be supplied with a sufficient quantity of UT-15C SR  to begin enrollment in the study .  
Appropriate arrangements will be made for resupply with respect to each subject’s visit schedule. A ll 
unused study drug dispensed to the subject should be returned to the study site (including empty and 
unopened bottles).   
Protocol Number TDE -PH-304 Amendment 5  Confidential  
United Therapeutics Corporation  
Final  Version Dated 20 March 2013  27 11.5 Study Drug Accountabilit y 
The Investigator is responsible for study drug accountability and reconciliation overall and on a per 
subject basis.  Drug accountability records are to be maintained during the study and these records 
include:  the amount of study drug received from the  Sponsor, the amount dispensed to each subject, and 
the amount of unused drug.  At each visit, site personnel should assess drug dispensed, drug returned, 
and dosing information to confirm drug accountability and compliance. Once a representative from the 
Sponsor is able to confirm drug accountability for that subject, study drug will be returned to a Sponsor 
designated location for destruction.  
12 REGULATORY AND ETHIC AL OBLIGATION  
12.1 Regulatory Requirements  
The study will be conducted in accordance with ICH and GCP guidelines and all applicable national 
regulations.  The Sponsor will obtain the required approval from each national regulatory authority to 
conduct the study.  During the conduct of the study an annual safety report will be compiled by the 
Sponsor for submission to those regulatory authorities and IRBs/ECs that require it.  Any additional 
national reporting requirements as specified by the applicable regulations, regulatory authorities, or 
IRB/EC will also be fulfilled during the conduct of th e study.  
12.2 Informed Consent Requirements  
Before a subject is enrolled in the study, the Investigator or his/her designees must explain the purpose 
and nature of the study, including potential benefits and risks and all study procedures to the subject.  
The subject must sign and date an IRB/EC -approved informed consent form prior to the conduct of any 
study -related activities.  A copy of the signed consent form will be given to the subject and the original will 
be retained in the study site’s records.  
12.3 Institutional Review Board/Independent Ethics Committee Approval  
Prior to study initiation at each site, the Investigator will obtain approval for the study from an appropriate 
IRB/EC and provide the Sponsor with a copy of the approval letter.  The IRB/E C must also review and 
approve the study site’s informed consent form and any other written information provided to the subject 
prior to enrollment, as well as any advertising materials used for subject recruitment.  Copies of the 
informed consent form and  advertising materials must be forwarded to the Sponsor for review before 
submission to the IRB/EC prior to the start of the study.  
If, during the study, it is necessary to amend either the protocol or the informed consent form, the 
Investigator is respons ible for obtaining IRB/EC approval of these amended documents prior to 
implementation.  Copies of the IRB/EC correspondence and approval letters must be sent to the Sponsor.  
During the conduct of the study, an annual progress report will be compiled by the  Sponsor for 
submission to those IRBs/ECs that require it.  
A written summary of the study will be provided by the Investigator to the IRB/EC following study 
completion or termination according to the IRB or EC standard procedures.  Additional updates will also 
be provided in accordance with the IRB/EC’s standard procedures.  
12.4 Prestudy Documentation Requirements  
 
Before the commencement of the clinical trial, the following documents will be provided to the site:  
Investigator’s Brochure, Protocol, Informe d Consent Form, Budget Agreement, and Case Report Form.  
 
The site will be required to provide the following documents to United Therapeutics Corporation or 
designee prior to study start:  Signature page of the protocol, Form FDA 1572, IRB/EC Composition an d 
Protocol Number TDE -PH-304 Amendment 5  Confidential  
United Therapeutics Corporation  
Final  Version Dated 20 March 2013  28 Roster, IRB/EC approval letters for protocol and informed consent, and Curriculum Vitae of study staff 
listed on the 1572.  
12.5 Subject Confidentiality  
 
Every effort will be made to keep medical information confidential.  United Therapeutics Corporation,  the 
FDA or other regulatory bodies, and the IRB/EC governing this study may inspect the medical records of 
any subject involved in this study.  The Investigator may release the subject’s medical records to 
employees or agents of the Sponsor, the IRB/EC or  the FDA or appropriate local regulatory agencies for 
purposes of checking the accuracy of the data.  A number will be assigned to all subjects and any report 
published will not identify the subject’s name.  
12.6   Reporting of Clinical Trial Results  
  
The timely communication of scientifically valid results, positive and negative, from this clinical trial will 
occur.   Avenues for such public communications may include the following:   peer-reviewed publications of 
original research and scientific, nonpromoti onal summaries on a publicly accessible registry ( i.e., a Web 
site).   A committee of principal investigators participating in the clinical trial and enrolling the highest 
number of subjects will oversee the publication of study results.  
  
The guidelines su ch as the Good Publication Practice (GPP) guidelines for pharmaceutical companies 
(gpp-guidelines.org ), and guidelines sponsored by the International Committee of Medical Journal Editors 
and the Pharmaceutical Manufacturers Association (PhRMA) will be endorsed.   In addition, an attempt 
will be made to fulfill any country specific regulatory r equirements for publication of clinical trials 
conducted within that country.  
13 ADMINISTRATIVE  AND LEGAL OBLIGATIONS  
13.1 Protocol Amendments  and Study Termination  
Protocol amendments that could potentially adversely affect the safety of participating sub jects or that 
alter the scope of the investigation, the scientific quality of the study, the experimental design, dosages, 
duration of therapy, assessment variables, the number of subjects treated, or subject selection criteria 
may be made only after consu ltation between United Therapeutics Corporation or its designee and the 
Investigator.  
All protocol amendments must be submitted to and approved by the appropriate regulatory authorities 
and IRB/Ethics Committee prior to implementation.  
A report documenting  study termination must also be submitted to and acknowledged by the appropriate 
IRB/EC for each study site.  
At the end of the study, where applicable, a final report will be provided to the local regulatory agencies.  
13.2 Study Documentation and Storage  
In accordance with federal/national regulations, ICH, and GCP guidelines, the Investigator must retain 
study records for at least 2 years after the last approval of a marketing application in an ICH region and 
until there are no pending or contemplated mark eting applications in an ICH region or at least 2 years 
have elapsed since the formal discontinuation of clinical development of the investigational product.  For 
investigators in the European Economic Area (EEA), the study records should be maintained for at least 
15 years after study discontinuation.   The Investigator must notify United Therapeutics Corporation before 
any disposal or change in location of study records.  
Protocol Number TDE -PH-304 Amendment 5  Confidential  
United Therapeutics Corporation  
Final  Version Dated 20 March 2013  29 13.3 Study Monitoring and Data Collection  
In accordance with federal/national regulatio ns, ICH, and GCP guidelines, monitors for United 
Therapeutics Corporation or its designee will periodically contact the site and conduct on -site visits.  
During these visits, the monitor will at a minimum:  confirm ethical treatment of subjects, assess stu dy 
progress, review data collected, conduct source document verification, verify drug accountability 
periodically, and identify any issues requiring resolution.   
The Investigator agrees to allow the monitor direct access to all relevant documents and to a llocate 
his/her time and his/her staff to the monitor to discuss any findings or any relevant issues.  
Protocol Number TDE -PH-304 Amendment 5  Confidential  
United Therapeutics Corporation  
Final  Version Dated 20 March 2013  30 14 REFERENCES  
1. Farber H. & Loscalzo  J.  Mechanisms of disease:  Pulmonary art erial hypertension.  New Engl J Med 
2004; 3511(16):1655 -1665.   
2. Barst RJ, Ru bin LJ, Long WA, et al.  A comparison of continuous intravenous epoprostenol 
(prostacyclin) with conventional therapy for primary pulmonary hypertension. New Engl J Med 1996; 
334:296 -301. 
3. Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, Rich S, Barst RJ, Barrett 
PS, Kral KM, Jobsis MM, Loyd JE, Murali S, Frost A, Girgis R, Bourge RC, Ralph DD, Elliott CG, Hill 
NS, Langleben D, Schilz RJ, McLaughlin VV, Robbins IM, Groves BM, Shapiro S, Medsger TA Jr. 
Continuous intravenous epoprostenol fo r pulmonary hypertension due to the scleroderma spectrum of 
disease. A randomized, controlled trial. Ann Intern Med. 2000; Mar 21; 132(6):425 -34. 
4. Simmoneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, Keogh A, Oudiz R, Frost A, 
Blackburn SD, Crow JW,  Rubin J.  Continuous subcutaneous infusion of treprostinil, a prostacyclin 
analogue, in subjects with pulmonary arterial hypertension: a double -blind, randomized, placebo -
controlled trial.  Am J. Resp. Crit Care Med. 2002; 165 (6):  800 -804. 
5. McLaughlin VV , Gaine SP, Barst RJ, et al. Efficacy and Safety of Treprostinil: An Epoprostenol 
Analogue for Primary Pulmonary Hypertension.  J. Cardiovascular. Pharm. 2003; 41(2):293 -9. 
6. Tapson VF, Gomberg -Maitland M, Horn E, Rich S, Krichman A, Ward G, Widlitz PA, Toms a L, Barst 
R.  Safety and Efficacy of Chronic Intravenous Treprostinil in Subjects with Pulmonary Arterial 
Hypertension – De Novo and Epoprostenol Transition.  Presented at American Thoracic Society, 
Orlando, FL, May 23, 2004.  
7. Laliberte K, Arneson C, Jeff s R, Hunt T, Wade M.  Pharmacokinetics and Steady -State 
Bioequivalence of Treprostinil Sodium (Remodulin®) Administered by the Intravenous and 
Subcutaneous Route to Healthy Volunteers.  Journal of Cardiovascular Pharmacol ogy. 
2004;44(2):209 -214. 
8. Ventavis P ackage Information.  Co Therix Inc., 2005; South San Francisco, CA  
9. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, 
Landzberg M, Simmoneau G.  Bosentan therapy for pulmonary arterial hypertension.  N Engl J Med. 
2002 Mar 21; 346(12):896 -903. 
10. Cohen H., Chahine C., Hui A., Mukherji  R.  Bosentan therapy for pulmonary arterial hypertension.  
American Journal of Health Systems Pharmacists, 2004; 61:1107 -19. 
11. Ghofrani H., Voswinckel R., Reichenberger F., Olschewski H., Haredza  P., Karadas  B., Schermuly 
R., Weissman N., Seeger W., Grimminger  F.  Differences in hemodynamic and oxygenation 
responses to three different phosphodiesterase -5 inhibitors in subject s with pulmonary arterial 
hypertension.  A randomized prospect ive study.  Journal of the American College of Cardiology, 
2004;44(7):1488 -96. 
12. Sastry B., Narahimhan C., Reddy N., Raju  B.  Clinical efficacy of sildenafil in primary pulmonary 
hypertension:  a randomized, placebo -controlled, double -blind, crossover study.   Journal of the 
American College of Cardiology 2004;43:1149 -53. 
13. Remodulin U.S. Package Insert.  Research Triangle Park, NC:  United Therapeutics Corporation.  
2011 . 